RECRUITINGPhase 1INTERVENTIONAL
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory Hyperlipidemia
About This Trial
VT-20101 is an Open-label, Phase 1b, Single-ascending dose study that will evaluate the safety of VERVE-201 administered to patients with Refractory Hyperlipidemia. VERVE-201 uses base-editing technology designed to inactivate the expression of the ANGPTL3 gene in the liver and lower circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides. This study is designed to determine the safety and pharmacodynamic profile of VERVE-201 in this patient population.
Who May Be Eligible (Plain English)
Who May Qualify:
- Refractory hypercholesterolemia
- Refractory hypertriglyceridemia
Who Should NOT Join This Trial:
- Active or history of chronic liver disease
- Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
- Clinically significant or abnormal laboratory values as defined by the protocol
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Refractory hypercholesterolemia
* Refractory hypertriglyceridemia
Exclusion Criteria:
* Active or history of chronic liver disease
* Current treatment with monoclonal antibody targeting ANGPTL3 or prior treatment within specified timeframe
* Clinically significant or abnormal laboratory values as defined by the protocol
Treatments Being Tested
DRUG
VERVE-201
Intravenous (IV) infusion
Locations (10)
Clinical Study Center
Adelaide, Australia
Clinical Study Center
Melbourne, Australia
Clinical Study Center
Chicoutimi, Canada
Clinical Study Center
Montreal, Canada
Clinical Study Center
Toronto, Canada
Clinical Study Center
Cape Town, South Africa
Clinical Study Center
Johannesburg, South Africa
Clinical Study Center
Liverpool, United Kingdom
Clinical Study Center
London, United Kingdom
Clinical Study Center
Manchester, United Kingdom